Ossium Health is pioneering a new paradigm in cell therapy by sourcing hematopoietic stem cells from deceased donors, a scalable and ethically distinct alternative to traditional bone marrow donation. The company has advanced its lead programs into clinical studies, with initial patients treated for transplant-related indications and orthopedics, and has secured significant partnerships with entities like NMDP and BARDA. Backed by over $125 million in venture funding from investors like First Round Capital, Vivo Capital, and General Catalyst, Ossium is positioned to address critical shortages in transplant medicine and expand into broader therapeutic areas.
HematologyTransplant MedicineOrthopedics
Technology Platform
Proprietary platform for recovering, processing, and banking hematopoietic stem and progenitor cells (HSPCs) from the bone marrow of consented deceased organ and tissue donors, creating a scalable source for cell therapies.
Funding History
3
Total raised:$75.5M
Series B$52MGeneral Catalyst
Series A$20MCobalt Ventures
Seed$3.5MY Combinator
Opportunities
Ossium addresses a critical global shortage of matched bone marrow donors, offering a scalable, off-the-shelf solution that could significantly reduce time-to-transplant.
Its platform enables expansion into large adjacent markets, including reducing immunosuppression in organ transplants and enhancing bone graft procedures in orthopedics.
Strategic government and non-profit partnerships (BARDA, NMDP) provide validation, funding, and a pathway to rapid deployment in both routine and emergency settings.
Risk Factors
The company faces significant clinical development risks, as the safety and efficacy of its novel cell source must be proven in ongoing trials.
Regulatory pathways for deceased donor-derived cells are complex and precedent-setting, potentially leading to delays.
Commercial success depends on convincing the established transplant community to adopt a new paradigm and on executing flawless logistics with organ procurement networks.
Competitive Landscape
Ossium's deceased donor model is distinct from primary competitors in the cell therapy space, which typically rely on autologous (patient's own) or allogeneic living donor cells. It competes indirectly with traditional bone marrow registries, cord blood banks, and companies developing ex vivo expanded stem cell products. In orthopedics, it faces competition from established bone graft substitute companies and other cellular orthobiologics developers.
